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ABSTRACT
Convalescent plasma can be transfused to patients suffering from the same infection or for preparing immunoglobulin concentrates. Plasma obtained 
from recovered patients can be a valuable alternative during the COVID-19 pandemic for supporting its treatment within a randomized or case-
control clinical trials or observational studies of plasma transfusion and for preparing plasma-derived biological products. WHO Blood Regulators 
Network highlighted that a systematic approach for collecting convalescent plasma from patients recovered from COVID-19 could provide a useful 
intervention. Structured clinical trials can be used to assess safety and effectiveness of convalescent plasma. The convalescent plasma therapy is still 
in the experimental stage and is currently not included in the interim clinical guidelines of WHO. However, an emergency investigational new drug 
application (eIND) process has been induced to ensure the availability of COVID-19 convalescent plasma to the patients with severe or life-threatening 
COVID-19 conditions. USFDA is regularly amending its guidance as new results, and best practices are emerging. The write-up provides an overview 
of convalescent plasma, from a regulatory considerations viewpoint, systematic workflow protocol, and a cross-section of clinical trials underway.
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INTRODUCTION
Plasma therapy emerged as a valuable approach for pathogen 
immunotherapy for acute infectious diseases, since the therapeutic 
effects of diphtheria antitoxin plasma in 1B91 were reported by 
Behring and Kitasato. In severe and critically ill patients of an emerging 
infection, the disease progression was rapid. During the starting 
phase, the target organs were damaged directly by the pathogens 
leading to severe immunopathological damage. These pathogens can 
be effectively and directly neutralized by passive immune antibodies 
reducing damage to the target organs and further blocking subsequent 
immunopathological damages [1].
Prevention and treatment of human infectious diseases by passive 
immunization started in the late 19th century. The possible use of 
whole convalescent blood and convalescent plasma for treating 
contagious diseases come into the spotlight during the Ebola virus 
outbreak in West Africa as it was the only therapeutic approach 
available in some cases due to the unavailability of drugs, vaccines, 
or other specific treatments [2,3]. Initially, the COVID-19 outbreak 
resulted in a high mortality rate due to a lack of effective and 
particular treatments. The non-availability of effective therapy for 
the COVID-19 pandemic has resulted in more than 1,160,000 deaths 
till October 27, 2020 worldwide. As mortality rate is an important 
parameter that concerns the public, clinical treatments that can 
decrease the fatality rate of critical cases virtually are urgently 
required to avoid public panic.
Researchers and scientists are continually searching for various 
treatment alternatives for developing vaccines and medicines to fight 
this life-threatening disease. Convalescent blood products can be a 
better alternative in the prophylaxis/treatment of some infectious 
diseases both as the single therapy when a specific treatment is 
not available and also in association with other drugs/preventive 
measures [4-7]. There are many potential convalescent plasma donors 
and critically ill patients requiring convalescent plasma treatment in 
hospital. Nevertheless, there are various arguments for considering 
the implementation of a large-scale convalescent plasma transfusion 
program [1].
CONVALESCENT PLASMA
Convalescent plasma refers to plasma obtained from a patient who has 
recovered from an infection. During the disease, the patient’s immune 
system escalates an attack on the invading virus, and the body develops 
antibodies [8,9]. These antibodies are suspended in the circulating 
blood and can be separated from one of the components of blood – the 
plasma [10]. Notably, convalescent plasma was found to be effective 
against the Spanish flu pandemic in 1918. At that time, convalescent 
plasma was used by the U.S. military to treat flu patients. More recently, 
WHO approved it as an empiric treatment against Ebola virus infections 
in 2015, and it was deployed with success against the SARS (severe 
acute respiratory syndrome) in 2002–2003 and middle east respiratory 
syndrome in 2012 as well [10-13].
In the context of COVID-19, FDA guidance has been issued that provides 
recommendations to health care personnel and investigators for 
the administration of investigational convalescent plasma obtained 
from individuals recovered from COVID-19 during the public health 
emergency. The guidance illustrates recommendations on the 
following aspects: (i) Pathways for the use of investigational COVID-19 
convalescent plasma, (ii) eligibility of patient (iii) collection of 
COVID-19 convalescent plasma, including eligibility and qualifications 
of donor, (iv) labeling of convalescent plasma, and (v) efficient record 
keeping [14].
Approaches for utilization of COVID-19 convalescent plasma
Since COVID-19 convalescent plasma is awaiting approval by the FDA, 
it is being used as an investigational drug. In these circumstances, 
health care personnel should follow one of the pathways detailed in 
Table 1. USFDA itself does not collect/provide COVID-19 convalescent 
plasma, but the product can be procured from an FDA registered blood 
establishment maintained by health care providers or acute care 
facilities [14].
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i2.39803. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
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Procedure for obtaining a single patient emergency IND
The request can be made by the provider at different time period during 
a day according to Eastern Standard Time (EST) as follows:
(i) For the requests between 8 am EST and 8 pm EST (Mon-Sun), the 
requesting physician may submit Form 3926 downloaded from 
https://www.fda.gov/media/98616/ by email to CBER_eIND_
Covid-19@FDA.HHS.gov. FDA will respond within four h for the 
eIND requests submitted through email during this time frame. The 
completed form should include:
•	 A short clinical background of the patient including the reason 
for the request for investigational convalescent plasma treatment 
with the purpose to meet the requirements mentioned in 21 CFR 
312.305 and 312.310.
•	 Name of the blood establishment collecting COVID-19 
convalescent plasma.
•	 The provider should fill the form electronically, if possible.
•	 Providers should ensure maximum completeness of the form, 
and the FDA will contact the provider if the need arises.
•	 The FDA will review the request and, upon validation, send 
the requesting physician a confirmatory email (including the 
emergency IND number).
(ii) For requests between 8 am EST and 8 pm EST when the provider 
cannot complete and submit the form FDA 3926 due to mitigating 
circumstances, the provider can contact the FDA’s Office of 
Emergency Operations to seek verbal authorization.
(iii) In case of a medical emergency, for the requests made between 8 
pm and 8 am, the convalescent plasma provider should necessarily 
obtain verbal authorization of the Food Drug and Administration 
office of Emergency Operations. If verbal consent is disposed of, 
the requesting physician must agree to submit an expanded access 
application (Form FDA 3926) within the time frame of 15 working 
days in accordance with section {21 CFR 312.310(d)(2)}.
Patient eligibility
For expediting the requests for eINDs to use COVID-19 convalescent 
plasma for treating severe patients, the patient eligibility criteria 
should be in accordance with the National Expanded Access Treatment 
Protocol. These include [14,16]:
•	 Age of ≥18 years.
•	 Laboratory confirmed COVID-19 report.
•	 Severe or immediately life-threatening COVID-19, as mentioned in 
Table 2.
•	 Informed consent is given by the patient or healthcare proxy.
•	 The blood type of patient. Convalescent plasma must be ABO 
compatible with the recipient’s blood type. 
Collection of COVID-19 convalescent plasma
It is mandatory for the acute care facilities and health care providers 
intending to use COVID-19 convalescent plasma, in the eIND submission, 
to mention that the COVID-19 convalescent plasma will be procured 
from an FDA-registered blood establishment that abides by the donor 
eligibility criteria and donor qualifications in the collection of plasma 
from donors as detailed below: 
Donor eligibility
a. Plasma can be collected from the individuals meeting all donor 
eligibility requirements according to 21 CFR 630.10, 21 CFR 
630.15. The additional donor eligibility requirements for plasma 
collection by plasmapheresis can be found in 21 CFR 630.15 
(b). Donated plasma should be tested for all the applicable 
transfusion-transmitted infections (21 CFR 610.40), and the donation 
must be satisfactory (21 CFR 630.30) [8].
b. The following qualifications should be met by the donor [14,20-22]:
•	 Confirmation of COVID-19 by a laboratory test either by a 
diagnostic test during illness OR by the presence of SARS-CoV-2 
Table 1: Pathways available for administering or studying the use of COVID-19 convalescent plasma [14]
Pathways Procedure/Protocol Section
Clinical trials To consider the application of convalescent plasma for a clinical trial, a request should be submitted by 
the investigators to FDA for the investigational purposes under the conventional IND regulatory pathway. 
Center for Biologics Evaluation and Research (CBER’s) Office of Blood Research and Review is responsible 
for dealing with investigators and reviewing these requests promptly. INDs can be submitted through email 
to CBERDCC_eMailSub@fda.hhs.gov during the current COVID-19 pandemic situation.
21 CFR Part 312
Expanded access For those patients with severe or immediately life-threatening COVID-19 disease who are ineligible or 
who are unable to take part in randomized clinical trials, an IND application for expanded access can be an 
option for using COVID-19 convalescent plasma. For opening an expanded access protocol so that COVID-19 
convalescent plasma can be made available across the country, the FDA has worked with multiple federal 
partners and academia. This investigational product can be accessed by the involvement of acute care 




Even though involvement in clinical trials or an expanded access program is pathways for patients to 
procure convalescent plasma, for several reasons, it may not be promptly available to all patients in 
potential need. Hence, during this public health emergency due to the COVID-19 pandemic, when clinical 
trials are undergoing, and a national expanded access protocol is available, USFDA is also encouraging 
availability of COVID-19 convalescent plasma to patients with severe or immediately life-threatening 
COVID-19 infections through submission of the request for a single patient emergency IND (eIND) for the 
individual patient from the patient’s physician. This pathway permits the utilization of an investigational 
drug for treating a particular patient under the supervision of a licensed physician upon FDA approval, if 
all the applicable eligibility criteria are fulfilled. However, under these conditions, an authorized physician 
should send a request for the eIND {see 21 CFR 312.310(b)} for administering COVID-19 convalescent 
plasma to an individual patient.
21 CFR 312.310
Table 2: Conditions defining severe and life-threatening COVID-19 [14-19]
Disease Severe disease Life-threatening disease
Conditions Shortness of breath (dyspnea) Respiratory failure
Respiratory frequency ≥30 min Septic shock
The ratio of partial pressure of arterial oxygen to the inspired oxygen should be <300 Multiple organ dysfunction or failure
Blood oxygen saturation ≤ 93% ----
More than 50% of lung infiltrates within 24–48 h ----
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antibodies after recovery (if initially diagnostic testing was not 
performed when COVID-19 was suspected).
•	 The donor should be completely symptom-free at least 14 days 
before plasma donation. Notably, a negative result for COVID-19 
by a diagnostic test is insufficient to meet the donor eligibility [23].
•	 The donor can be either male or female. For females, the donor 
should not be pregnant or has negative report for human 
leukocyte antigen (HLA) antibodies.
•	 The body weight for male donors should be > 50 kg and > 45 kg 
for females.
•	 At least 1 week since last glucocorticoid usage.
•	 More than 2 weeks since the last blood donation.
•	 Establish SARS-CoV-2 neutralizing antibody titers.
The neutralizing antibody titers should be at least 1:160 [24]. A titer 
of 1:80 is admissible if another matched unit is not accessible. In 
case, neutralizing antibody titers cannot be measured, a retention 
sample from the donated convalescent plasma must be stored for later 
determination. However, storing samples for single patient eINDs is not 
recommended. 
For the registered and licensed blood establishments already authorized 
for plasma collection for transfusion need not seek an additional license 
or procure their own IND for collection and preparation of COVID-19 
convalescent plasma for the investigational purpose provided they 
1. Follow their SOPs for plasma collection and all applicable regulations, 
and 
2. Collect plasma from individuals meeting the donor qualifications 
detailed above. Once prepared, the COVID-19 convalescent plasma 
may be distributed for investigational use. Blood establishments do 
not need to seek an alternative pathway or exception under section 
21 CFR 640.120(a) to collect the COVID-19 convalescent plasma.
Labeling
The labeling requirements recommendations are:
a. The label of COVID-19 convalescent plasma container must mention 
the statement, “Caution: New Drug--Limited by Federal (or US) law to 
investigational use.” {21 CFR 312.6(a)}. In addition, the requirements 
in 21 CFR 606.121 for the container label applies, along with inclusion 
of a note for the circular of information (on use of plasma).
b. FDA recommends the use of a uniform container label for COVID-19 
convalescent plasma. Specifically, the uniform labeling of blood and 
blood components using ISBT 128 has been recommended.
c. The shelf-life and storage guidelines on the label for COVID-19 
convalescent plasma should be the same as for other plasma products. 
For example, fresh frozen COVID-19 convalescent plasma should be 
frozen within eight hour after collection, stored at ≤18°C, and labeled 
with a shelf-life of one year from date of collection [14,22].
Recordkeeping 
The records for the COVID-19 convalescent plasma unit(s) administered 
to the COVID-19 patient (21 CFR 312.62) must be maintained by health 
care provider. These records should include the unique identification 
number of the plasma units [22].
AUTHORISATION OF CONVALESCENT PLASMA COLLECTION, 
TESTING, PROCESSING, STORAGE, AND DISTRIBUTION
The blood establishments meeting the criteria for donation, collection, 
processing, and testing are authorized by competent authority to 
proceed unless the National regulatory authority enforces more 
stringent requirements or their existing authorization already 
covers the activities for plasma transfusion, including convalescent 
plasma [25]. This facilitates the rapid creation of national inventories of 
COVID-19 convalescent plasma.
Blood establishments that have adopted measures for gathering 
outcome data to ensure safety and quality can be authorized for 
convalescent plasma distribution [21].
Collection, processing, and storage
Instead of whole blood, plasmapheresis is preferred to improve the yield 
of convalescent plasma. Apheresis is an automated technology in which 
whole blood is continuously centrifuged into its components (namely, 
red blood cells, platelets, and plasma), followed by a selective collection 
of the desired blood component returning remaining components to 
the donor. This highly efficient procedure generates around 400–800 ml 
of plasma from a single apheresis donation. In general, donors donate 
plasma by plasmapheresis, but if such facilities are not available, whole 
blood can be collected, followed by plasma separation in the blood 
establishment [26]. For those repeating donation, an average donation 
gap of 2 weeks is advised. 
Plasma obtained by plasmapheresis should be divided into 2–3 separate 
units (3 × 200 ml) before freezing. The units are frozen within 24 h of 
collection and quarantined until reports are obtained from standard 
blood donor testing for transfusion-transmitted infections. Final 
products should be appropriately labeled as COVID-19 convalescent 
plasma/blood and appropriately stored. Pathogen reduction should 
be done if it is normally followed in the blood establishment and 
care should be taken not to introduce pathogen. Any serious adverse 
reactions in the donor should be notified to the competent authority 
without delay [21,27,28].
Testing of donated plasma
In addition to the general quality-control tests and the test for blood-
borne diseases, the blood samples need to be tested for:
(1) Nucleic acid testing for SARS-CoV-2;
(2) 160-fold dilution for the qualitative test of SARS-CoV-2 specific lgG 
and lgM detection; or 320-fold dilution for the qualitative test of 
whole antibody detection. If possible, keep aside >3 mL of plasma 
for the viral neutralization experiments.
While comparing virus neutralization titer and luminescent lgG 
antibody quantitative detection, it was found that the present SARS-
CoV-2 specific lgG antibody detection does not fully demonstrate the 
actual virus neutralization capability of the plasma. Therefore, the virus 
neutralization test was suggested as the first choice, or determines the 
overall antibody level with the 320-fold dilution of the plasma [29]. It 
is recommended that neutralizing antibody titers should optimally be 
more than 1:320, but lower thresholds might also be clinically effective. 
When the measured neutralizing activity in the collected plasma is 
found to be low, the plasma can be fractionated and used for other 
clinical applications.
Ideally, a test for the existence of the anti-SARS-CoV-2 antibody 
should be accomplished through neutralizing antibody testing 
before using convalescent plasma. In case of emergency, where 
convalescent plasma is transfused without antibody testing, a sample 
should be stored and tested later. If an appropriate correlation can 
be demonstrated between neutralizing activity and Elisa antibody 
testing, it can replace the neutralizing antibody test. Therefore, it is 
suggested that additional samples of the donated plasma should be 
archived for reference studies. Thus 10 × 0.5 mL frozen aliquots from 
plasma samples can be withdrawn at the time of donation. In the 
case of repeated donations, plasma should be collected from donors 
showing higher titers rather than the ones with lower titers, based on 
the collection capacity [21,27].
Distribution of COVID-19 convalescent plasma
Blood establishments can distribute convalescent plasma to a hospital, 
on the request, when the specific patient 
•	 Has laboratory-confirmed COVID-19,
•	 Has been hospitalized either due to acute illness or risk of acute 
illness,
•	 Has accorded informed consent.
It is advisable to inform the potential recipient(s) about the uncertainty 
in the efficacy of convalescent plasma therapy in treating COVID-19 to 
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avoid promoting unsubstantiated expectations. The recipient may be a 
part of a clinical trial or monitored use. This helps in making informed 
decisions regarding treatment by the prospective recipients.
Blood services should provide convalescent plasma with the highest 
antibody titers available. Furthermore, the dose of transfused plasma 
should be adjusted based on its neutralizing antibody titer and the 
volume of plasma of the recipient. Convalescent plasma in an approved 
randomized or case-controlled clinical trial should be distributed 
as per the protocol of that trial and, where necessary, in compliance 
with national legislation [21,30,31]. To ensure safety, quality, and 
amend improvements in the collection, testing, processing, and storage 
protocols, the hospitals should furnish defined clinical outcomes to the 
supplier blood establishment [32]. The information to be included in 
the outcome data should entail:
1. Gender, co-morbidities, age range (20–29, 30–39, etc.), 
2. Transfusion time point (days from the onset of disease)
3. Volume, number, and antibody titer of the transfused plasma unit
4. Clinical treatment given to the patient in parallel (other than 
supportive care)
5. Clinical symptoms and laboratory parameters according to the 
progression of disease at the following time points (i) before the 
transfusion, (ii) more than 5 days after transfusion, and (iii) at 
discharge (if the patient survives)
6. Length of hospitalization (if the patient survives).
7. Any adverse reactions or events potentially linked to the transfusion. 
The outcome data in the above format should be reported to the 
supplying blood establishments and, through them, to the national 
database to establish a comprehensive scenario at the national level. 
The data from controlled clinical trials should be first evaluated 
according to a pre-defined analytical strategy in the clinical trial 
protocol and published as early as possible. The minimum outcome 
data should also be reported to the national database to allow meta-
analysis in a larger dataset later on. Severe adverse reactions or events 
possibly linked to the transfusion should be notified by the hospitals 
to the supplying blood establishments and after that to the competent 
authority without delay. This reporting is essential whether the plasma 
has been transfused in an observational study or a controlled clinical 
trial [21].
PROCEDURE FOR CONVALESCENT PLASMA THERAPY PHASE 
Consecutively critically ill patients admitted to the intensive care unit, 
or other areas of the hospital should be selected based on the following 
criteria [33]: 
Inclusion criteria 
Same as discussed for patient eligibility
Exclusion criteria 
1. Negative Reverse transcription-polymerase chain reaction (RT-PCR) 
of respiratory secretion samples. 
2. Reported history of a hypersensitive reaction to blood products or 
plasma.
3. Clinical situation where in administering 500 ml i.v. volume may be 
harmful to the patient (e.g., actively decompensated congestive heart 
failure). 
4. Severe multi-organ failure, hemodynamic instability. 
5. Other documented uncontrolled infection. 
6. Patient is expected to survive for <48 h. 
7. Severe DIC (disseminated i.v. coagulation) needing factor 
replacement, fresh frozen plasma (FFP), and cryoprecipitate.
Informed consent 
The treating physician and/or the protocol coordinator will describe 
the purpose of this intervention and its possible benefits and risks to 
the patient or donor (or to his/her surrogate decision-maker). They 
will obtain the following consent forms in and as appropriate [33]. 
For the collection of convalescent plasma 
1. Informed consent for COVID-19 RT-PCR and COVID-19 serologic 
testing for the donors. 
2. Informed consent for donation of convalescent plasma from those 
with elevated anti-SARS-CoV-2 titers as described below.
For the Convalescent plasma therapy phase 
A. Consent for enrollment in the convalescent plasma therapy phase
B. Protocol procedures for the convalescent plasma collection phase
1. Eligible candidates for convalescent plasma donation (as per 
the inclusion and exclusion criteria above) will be tested for 
anti- SARS-CoV-2 serology. Subjects who are seropositive will 
be further screened for SARS-CoV-2 RT-PCR. 
2. Subjects with an anti-SARS-CoV-2 titer of either more than or 
equal to 1:80 and negative rRT-PCR conformation of COVID-19 
infection will be selected for qualification for donating plasma 
according to the standard criteria following the WHO guidelines 
assessing donor acceptability for donating blood. 
3. Individuals fulfilling all the criteria for the plasma donation will 
be called for donation. 
Apheresis may be used to collect plasma (500–600 ml on the basis of 
weight), as suitable for every donor [34]. The collection will be made by 
trained personnel of blood bank working as per the standard operating 
procedures in certified laboratories. The frozen plasma is stored at 
appropriate temperature in the blood bank after reported negative 
for a series of serological tests in accordance to the international 
guidelines [20,33,35]. 
Infusion plan 
The general dosage of convalescent plasma therapy is ~400 ml for 
one infusion or ~200 ml per infusion for multiple infusions. The 
intervention consists of administering 2 units of convalescent plasma. 
Both the units of plasma (200–250 ml) should be infused over 2 h 
maintaining a gap of 1 h between the two units. Plasma transfusion will 
be done as per the standard policies recommended for administering 
blood products [33,36]. 
Clinical cointerventions 
The clinical team exercises independent control of patient management 
other than convalescent plasma therapy and will not be influenced 
by the intervention team. Co-interventions such as administration of 
hydroxychloroquine, Kaletra or darunavir/cobicistat, azithromycin, 
tocilizumab, corticosteroids, ribavirin, and interferon will be recorded 
on the patient report sheets. The frequency of clinical and laboratory 
assessment follow-up is done at baseline, followed by day 1, 3, 5, 7, 14, 
and after 28 days after administration of convalescent plasma [33].
Outcome measures 
These may be classified as clinical and laboratory outcomes, as 
mentioned in Table 3.
Safety measures 
Under conditions of an acute transfusion reaction, the transfusion 
should be stopped immediately and must be reported immediately to 
the blood bank, the principal investigator and the study management 
committee. All the serious adverse events related to the convalescent 
plasma should be recorded [16,33,38].
CLINICAL USE OF THE CONVALESCENT PLASMA
Indication
(1) Severe or critically ill COVID-19 patients tested positive in respiratory 
tract test;
(2) The COVID-19 patients who are not severe or critically ill, but in a state 
of immunity suppression; or have low CT (cycle threshold) values in 
the virus nucleic acid testing but with a rapid disease progression 
in the lungs [36].
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Contraindication
1. Allergy history of plasma, sodium citrate, and methylene blue;
2. For patients with a history of autoimmune system diseases or 
selective lgA deficiency, the application of convalescent plasma 
should be evaluated cautiously by clinicians [36,39-42].
Convalescent plasma trial for COVID-19 in India
Central Drugs Standard Control Organization (CDSCO) of India has 
entrusted permission to the Indian Council of Medical Research 
(ICMR) for the clinical trial of convalescent plasma for COVID-19 
therapeutics. A list of institutes interested in conducting clinical 
trials has been submitted by the ICMR. The trial shall be conducted 
as an open-label, randomized, controlled Phase II study to assess the 
safety and efficacy of convalescent plasma in patients with moderate 
COVID-19 disease. Encouraging results were obtained in a small case 
involving five critically ill COVID-19 patients with acute respiratory 
distress syndrome (ARDS). Infusion of convalescent plasma containing 
neutralizing antibodies led to substantial clinical improvement in all 
patients without any deaths [43]. In another group of four patients that 
included one pregnant woman, convalescent plasma transfusion led to 
complete recovery eventually [44,45]. 
In the light of public interest, the ICMR’s proposal for conducting a trial 
was reviewed by the Subject Expert Committee in its meeting held on 
13 April under the accelerated approval process owing to the prevailing 
pandemic. Further, no objection was raised by the CDSCO for the 
conduct of clinical trial subject to few amendments in the trial protocol 
and various conditions specified in the Drugs and Clinical Trial Rules, 
2019 [46].
The Union Health ministry released clinical management protocols 
for COVID-19 on June 27, 2020. They allowed the use of convalescent 
plasma (off-label) to treat COVID-19 patients in a moderate stage 
of the illness under “investigational therapies,” as mentioned in the 
CDSCO notice, “Information on Convalescent Plasma in COVID-19.” 
As per the CDSCO notice, convalescent plasma may be used in 
moderately infected patients and those that are not improving (the 
oxygen requirement is progressively increasing) despite the steroidal 
therapy. Further, the recipient should be kept under strict observation 
for several hours after transfusion to monitor any adverse events. The 
application of convalescent plasma should be prevented in patients 
with immunoglobulin allergy of immunoglobulin A deficiency [47].
CLINICAL TRIALS TO ASSESS THE EFFICACY AND SAFETY OF 
HUMAN ANTI-SARS-COV-2 PLASMA
The use of convalescent plasma has documented successful historical 
records, as many controlled trials have been conducted to assess its 
efficacy as an emergency application during epidemics. In the current 
situation, at least five clinical trials should be carried out to evaluate the 
effectiveness of human anti-SARS-CoV-2 plasma for the prevention and 
treatment of COVID-19. 
The first trial involves the use of human anti-SARS-CoV-2 plasma as 
post-exposure prophylaxis: a randomized, blinded Phase II trial for 
comparing the safety, and efficacy of human anti-SARS-CoV-2 plasma 
against control (SARS-CoV-2 non-immune plasma) in adults (age more 
than 18 years) who have had close contact exposure to COVID-19, but 
are asymptomatic. Close contact exposure refers to be in the periphery 
of within approximately 2 m (6 ft) of a COVID-19 patient for a substantial 
duration without personal protective equipment. Close contact also 
refers to living with, visiting, caring for, or sharing a healthcare waiting 
area or room with a COVID-19 infected individual or direct contact with 
infectious secretions of a COVID-19 patient without PPE. 
If the first trial is successful, safe, and effective, post-exposure 
prophylaxis will offer therapeutic intervention for vulnerable 
populations, namely immunocompromised patients, health care 
workers, nursing home residents, and individuals with respiratory, 
following exposure. This would confer direct clinical benefit for those 
at high risk and would impact more significant social benefits to the 
frontline workers in the pandemic.
The second trial will assess human anti-SARS-CoV-2 plasma for 
offering initial help to mildly infected patients. The target population 
can be symptomatic individuals with confirmed SARS-CoV-2. The 
clinical endpoints would be the prevention of hypoxemia in room air, 
suppression of symptoms, or progression to severe disease, reflecting a 
decline in complications not requiring hospitalization. 
In the third trial, moderately ill patients will be investigated to assess 
the effect of human anti-SARS-CoV-2 plasma on them. The target 
population will be hospitalized COVID-19 patients showing clinical 
symptoms but not requiring ICU admission (specifically mechanical 
ventilation). Aversion to critical illness could avoid overburdening of 
essential resources of care.
A fourth trial could assess whether human anti-SARS-CoV-2 plasma can 
act as a rescue intervention in COVID-19 patients requiring mechanical 
ventilation. This target group is significant as it is a group, for which the 
data are most challenging to interpret due to the confounding variables, 
including other putative therapies for COVID-19.
Finally, a fifth trial evaluates the safety and pharmacokinetics of 
convalescent plasma in high-risk pediatric patients. Although 
comparatively rare, severe illness, and even deaths due to COVID-19 
have been described in children [48], requiring the need to address the 
risk to children.
Complementing these four trials, studies are being designed to collect 
and mine data from emergency use of convalescent plasma or expanded 
access treatment.
REPORTED CLINICAL TRIALS 
Institute of Liver and Biliary Sciences, India, has undertaken clinical trials 
to determine the effectiveness of convalescent plasma therapy in severely 
infected COVID-19 patients. A randomized controlled trial was planned to 
evaluate the efficacy of this therapy in COVID-19 patients. Five hundred 
milliliters of convalescent plasma were collected from the COVID-19 
recovered patient after 14 days of clinical and radiological recovery with 
two consecutive COVID-19 negative tests by PCR. Further, the samples 
from the collected plasma for COVID-19 specific antibodies and their 
titer were tested. This plasma was frozen and sent to the treating center 
(Maulana Azad Medical College). 200–600 ml of convalescent plasma was 
transfused to patients fulfilling the eligibility criteria and was randomized 
Table 3: Outcome measures of convalescent plasma therapy [30,33,37]
Clinical outcomes Laboratory outcomes
Sequential organ failure assessment score on day 1, 3, 5, 7, 14, and 28 Virological clearance at day 7, 14, 21
Ventilator free days CT values for SARS-CoV-2 PCR positivity (RT-PCR) at days 0, 7, 21 when 
available
ICU mortality and LOS Determining anti-SARS-CoV-2 titers at day 0 and thereafter
Hospital mortality and LOS -----
Multi-organ failure -----
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to the convalescent plasma group. This was accomplished in critically ill 
patients. The data were collected for the clinical benefit and monitored 
the adverse events related to the transfusion [17].
Globally, various clinical trials have been recruited or are yet to be 
recruited to evaluate the efficacy of convalescent plasma therapy in 
COVID-19 patients. A few of them are listed in Table 4.
Study title Intervention Status Location
Convalescent plasma trial in 
COVID-19 patients [51]
Other: Plasma therapy using 
convalescent plasma with the 
antibody against SARS-CoV-2
Other: Routine care for 
COVID-19 patients
Completed Royal College of Surgeons, Ireland
Convalescent Plasma Therapy vs. 
SOC for the Treatment of COVID19 
in Hospitalized Patients [52]
Other: Blood and derivatives.
Drug: Standard of Care
Recruiting Hospital Clínico Universitario Lozano Blesa 
Zaragoza, Aragón, Spain
Hospital Universitario Severo Ochoa Leganés, 
Madrid, Spain
Hospital Universitario Puerta de Hierro 
Majadahonda 
Majadahonda, Madrid, Spain
Efficacy of convalescent plasma 
therapy in severely sick COVID-19 
patients [17]
Drug: Convalescent Plasma 
Transfusion
Other: Supportive Care
Drug: Random Donor Plasma
Completed Maulana Azad medical College 
New Delhi, Delhi, India
Institute of Liver and Biliary Sciences 
New Delhi, Delhi, India
Convalescent Plasma as Therapy 
for Covid-19 Severe SARS-CoV-2 
Disease (CONCOVID Study) [53]
Biological: Convalescent plasma Recruiting Erasmus Medical Center Rotterdam, Zuid-Holland, 
Netherlands
NoordWest Ziekenhuisgroep Alkmaar, Netherlands
Onze Lieve Vrouwen Gasthuis Amsterdam, 
Netherlands
Efficacy of Convalescent Plasma 
Therapy in Patients With  
COVID-19 [54]
Biological: Convalescent Plasma
Other: Standard of Care
Recruiting Maulana Azad Medical College, New Delhi, India
Institute of Liver & Biliary Sciences, New Delhi, 
India
Rajiv Gandhi Super Specialty Hospital New Delhi, 
India
Convalescent Plasma Therapy in 
Patients With COVID-19 [55]
Biological: Convalescent plasma Completed Gatot Soebroto central army presidential hospital 
Jakarta Pusat, Indonesia
Convalescent Plasma Therapy on 
Critically-ill Novel Coronavirus 
(COVID-19) Patients [56]
Biological: Convalescent plasma
Drug: Hydroxychloroquine with 
Azithromycin
Completed Alkarkh Health directorate Baghdad, Iraq
Convalescent Plasma Therapy in 
Severe COVID-19 Infection [57]
Biological: Convalescent plasma Recruiting Bangabandhu Sheikh Mujib Medical University 
Dhaka, Bangladesh
Amotosalen-UV A pathogen-
inactivated convalescent plasma 
in addition to best supportive care 
and antiviral therapy on clinical 
deterioration in adults presenting 
with moderate to severe  
COVID-19 [58]
Other: Convalescent plasma 
administration to SARS-CoV-2 
infected patients
Completed Blutspendezentrum SRK beider Basel, University 
Hospital Basel, Switzerland 
Convalescent Plasma for Treatment 




Recruiting Danderyd Hospital, Danderyd, Stockholm, Sweden
Karolinska University Hospital, Stockholm, Sweden
Convalescent Plasma Treatment in 
COVID-19 [60]
Biological: convalescent 
plasma (CP) Other: Drugs and 
supportive care
Recruiting Aga Khan University Hospital, Karachi, Sind, 
Pakistan
Evaluation of SARS-CoV-2 
(COVID-19) Antibody-containing 
Plasma therapy [61]
Biological: High-Titer COVID-19 
Convalescent Plasma (HT-CCP)
Biological: Standard Plasma
Recruiting Brigham and Women’s Hospital, Boston, 
Massachusetts, United States
Plasma therapy of COVID-19 in 
critically ill patients [62]




Recruiting Columbia University Irving Medical Center/NYP 
New York, New York, United States 
Treatment of patients with 
COVID-19 with convalescent 
plasma [63]
Biological: convalescent plasma Recruiting General Hospital, University of Sao Paulo, Brazil 
Convalescent plasma for the 
treatment of COVID-19 [64]
Drug: Convalescent plasma Recruiting Thomas Jefferson University Hospital, Philadelphia, 
Pennsylvania, United States
Assessment of the effect of 
convalescent plasma therapy in 
patients with Life-threatening 
COVID19 infection [65]
Biological: Convalescent plasma Recruiting Cairo University Hospital 
Cairo, Egypt
Table 4: Details of clinical trials to assess the efficacy of convalescent plasma therapy in COVID-19 patients [49,50]
(Contd...)
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CONCLUSION
The risks due to COVID-19 infection are vast. Convalescent plasma 
obtained from recovered COVID-19 patients has been proposed to 
be a potentially effective and safe therapy for treatment and post-
exposure prophylaxis alike. Several evidence of benefit with prior use 
for viral infections offers strong precedent for such an approach. The 
availability of limited data from precisely controlled clinical trials of 
convalescent plasma necessitates evaluating its use objectively for a 
range of indications and patient populations. However, performing 
well-controlled clinical trials is critically important to confirm efficacy, 
so rational evidence-based decision-making can be made.
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